Fall 2023 LipidSpin Articles
Daniel E. Soffer, MD, FNLA |
Letter from the NLA President: Charging AheadHello NLA members, I hope everyone had a wonderful summer. As our long, warm days move into cool fall nights, the NLA continues to charge ahead, expanding educational opportunities for providers to combat the rise of cardiovascular disease. The fall CLU in Scottsdale, Arizona, will go off without a hitch. We have a fantastic line up of faculty and we greatly appreciate their participation. “Talking lipids” with my longtime friends and befriending so many new lipid colleagues is my... more |
Lynne T. Braun, PhD, CNP, CLS, FNLA |
Editor's Corner: Why are CVD Deaths on the Rise?Cardiovascular disease (CVD) remains the #1 killer of American men and women. Following recognition of the large gap between deaths of women as compared to men in the year 2000, there was subsequent intense focus on prevention of CVD in women. Following the launch of campaigns such as Go Red by the American Heart Association and Heart Truth by the National Heart, Lung, and Blood Institute, CVD deaths sharply declined in both women and men. Health care professionals and the public were... more |
Roda Plakogiannis, PharmD, BCPS, BCACP, CLS, FNLA |
From the NELA President: Diabesity: The Silent EpidemicLiving in New York City, specifically the Upper East Side (UES), the congestion of food delivery workers 24/7 has become the norm. There are an estimated 65,000 delivery workers to meet the needs of the continuous rise of the fast-food franchise in NYC. You may recall from Sex and the City that Carrie Bradshaw used her oven as extra closet space; this is not far-fetched from the truth of upper east side culture. The lack of time to prepare homemade meals has resulted in detrimental health... more |
Jan McAlister, DNP, CLS, FNLA |
Letter from the SELA President: What are Cardiometabolic Disorders?Dr. Google, referencing ACC, tells us that cardiometabolic disorders represent a cluster of interrelated risk factors, primarily hypertension, elevated fasting blood sugar, dyslipidemia, abdominal obesity, and elevated triglycerides. Examples of the disease include heart attack, stroke, diabetes, insulin resistance, nonalcoholic fatty liver disease, and chronic kidney disease. Being a member of the NLA since 2001, I have witnessed multiple editions and LipidSpin... more |
Jared Segal, DO Prem Raj Parajuli, MD Dharmesh Patel, MD, MBBS (Lon), FACC, FACP, FNLA, FASPC, RVPI Aniruddha Singh, MD, FACC |
Clinical Feature: The Intersection of Diabetes, Obesity, and DyslipidemiaIntroduction/Magnitude of The Problem Diabetes mellitus (DM) is a systemic disease of abnormal carbohydrate metabolism leading to chronic hyperglycemia. It is a major contributor to chronic disease and death, both in the United States (U.S.) and globally. Notably, more than 37 million U.S. adults have diabetes mellitus with type 2 diabetes accounting for approximately 90-95% of this population. Moreover, diabetes is the 8th leading cause of... more |
Dimitra Bantouna, MD Rodis D. Paparodis, MD, FNLA |
Guest Editorial: Diabetes and Obesity: Transatlantic Considerations on a Global Public Health IssueDefinitions Obesity is defined as the presence of abnormal or excessive fat accumulation, which increases the risk for conditions with negative impact on human health, such as diabetes mellitus and cardiovascular disorders, among others. It is diagnosed when the body mass index (BMI) is at or above 30 kg/m2. Obesity is causally related to several metabolic complications, including type 2 diabetes (DM2), where >50% of new cases are believed to be... more |
Mabel Chan, PharmD, BCACP, BC-ADM Stephanie Cardinale, PharmD, BCACP |
EBM Tools for Practice: Navigating the Complexities: Cardiometabolic Disease Management in Chronic Kidney PatientsIntroduction Cardiometabolic syndrome is an aggregation of cardiovascular, metabolic, and renal abnormalities that includes central/visceral obesity, hyperinsulinemia, hypertension, and dyslipidemia.1 Approximately 47 million individuals in the United States are currently living with cardiometabolic disorders, placing them at a higher risk of developing chronic conditions.2 There is an overwhelming amount of epidemiologic evidence demonstrating... more |
Rachel Tobin, MD Gina Lundberg, MD, FACC, FAHA |
Lipid Luminations: Novel Advancements in GLP-1 Receptor Agonist TreatmentIntroduction Obesity is a complex, chronic medical condition. Although defined by a BMI >30 kg/m2, it is now understood to be much more than a BMI cutoff and modulated by neuroendocrine mechanisms with emerging therapeutic options.1,2 Clinical guidelines recommend medical treatment for obese or overweight patients with at least one weight-related comorbidity.3 Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted from gut... more |
Merle Myerson, MD, EdD, FACC, FNLA Wayne Warren, MD, FNLA Sarah Miller, RD Anna Biggins, MPH, RDN, LD |
Specialty Corner: Medical Nutrition Therapy for Pre-Diabetes, Diabetes, and Obesity in AdultsMedical nutrition therapy (MNT) by trained registered dietitian nutritionists (RDN) is an integral part of a multidisciplinary health care team. Research has shown that this therapy is clinically beneficial and cost effective.1,2,3 For patients with cardiometabolic disease, in particular diabetes and obesity, it is essential for optimizing quality of life and prevention of manifest cardiovascular disease. This article provides information on dietary plans and counseling aligned... more |
Cindy Nee, PharmD Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA |
Practical Pearls: Addressing Medication Adherence in Obesity and DiabetesMedication Adherence Medication adherence is a vital part of managing a patient’s medication regimen but is often overlooked. Between addressing patient symptoms, assessing vital signs, and dispensing medications, healthcare providers have several tasks to address during a patient encounter. However, without addressing the importance of medication adherence, patients oftentimes will not take prescriptions as prescribed, leading to subtherapeutic response to... more |
Naz Baecher, MD Robert Block, MD, FNLA Greg Pokrywka, MD, FACP, FASPC, NCMP, FNLA |
Case Study: Pharmacotherapy for Dyslipidemia and Metabolic Dysfunction-Associated Steatotic Fatty Liver DiseaseClinical Case The patient is a 67-year-old white gentleman with type 2 diabetes mellitus (T2DM), hypertension (HTN), 20-pack-year smoking history, and dyslipidemia. He presented to the Lipidology Clinic for a follow-up of his diabetes and atherogenic dyslipidemia. He has never experienced any atherosclerotic cardiovascular disease (ASCVD) events. Due to his moderate risk profile, the decision was made to perform an advanced “carotid-femoral plaque scan”1-6... more |
Caroline deRichemond, CRNP, CLS, FNLA |
NELA Chapter Update: Hitting the Spotlight on NELA's Shining StarsThis Fall 2023 edition of the LipidSpin on Diabesity is sponsored by NELA and SELA Chapters. The 2023 NELA Chapter and Board would like to thank all the authors, contributors, and editors who shared their expertise to make this an informative and valuable issue of LipidSpin. Despite the healthcare challenges post pandemic of patient backlogs, increasing RVU’s, budget cuts and the increased challenges in traveling, the NELA membership presence was noted at the 2023... more |
Kathleen Byrne, CRNP, FPCNA, MS, CLS, FNLA |
SELA Chapter Update: SELA Members are Engaged, Involved, and Making an Impact within Their CommunitiesThe 2023 Scientific Sessions in June were well attended and provided superb learning opportunities for all. As always, this was a time to connect and network with old and new colleagues and friends. SELA president, Jan McAlister, DNP, CLS, FNLA and Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA served on the Planning Committee and several members were Faculty, including: Vera Bittner, MD, MSPH, MNLA |
James A. Underberg, MD, MS, MNLA |
Foundation of the NLA Update: Big Things Happening!The Foundation of the NLA did something a little different this year – instead of hosting a black-tie gala event, we opted for a more casual affair, filled with light bites and vintage arcade games! The evening was full of good conversation, and friendly competition. We appreciate those who made it to our event to support our efforts educating patients on lipid-related health problems. The game night entrees and silent auction donations netted the Foundation $10,400 in just one night! We... more |
National Lipid Association |
2023 Scientific Sessions Abstract Award WinnersThe National Lipid Association (NLA) is pleased to announce that 90 abstracts were accepted for presentation in the poster format for the NLA 2023 Scientific Sessions. Each abstract was reviewed by the NLA Scientific Sessions Abstracts Committee prior to acceptance. Posters were judged on quality of science, originality, interest to the field of lipidology, and overall impression. The first place Young Investigator and Donald Hunninghake FH winner were selected to give an oral presentation... more |
National Lipid Association |
Member Spotlight: Lipid Scholarship Recipients
Oby B. Ibe, MD, MPH is a third year General Cardiology fellow at Temple University Hospital. She completed her Internal Medicine Residency at the Hospital of the University of Pennsylvania and earned a Master’s in Public Health from the Milken Institute School of Public Health. Her... more |